5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-(hydroxymethyl)isoxazole | 107355-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-(hydroxymethyl)isoxazole
• 英文别名: 5-{5-[2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]pentyl}-3-isoxazolemethanol；3-(Hydroxymethyl)-5-[5-[2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy]-pentyl]-isoxazole；[5-[5-[2,6-dichloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl]-1,2-oxazol-3-yl]methanol
• CAS: 107355-85-1
• 化学式: C₁₈H₂₀Cl₂N₂O₄
• 分子量: 399.274
• InChiKey: ZCPRWNJVTYPOMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-(hydroxymethyl)isoxazole 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 碳酸氢钠 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 81.0h， 生成 3-(1-(9-fluorenylmethoxycarbonylamino)-3,6,9,12-tetraoxaundecyl)-5-[5-[2,6-dichloro-4(4,5-dihydro-2-oxazolyl)phenoxy]-pentyl]-isoxazole
  参考文献：
  名称：

  Antiviral agents

  摘要：

  这项发明涉及一种能够结合至小RNA病毒外壳的化合物，包括两个或更多外壳结合基团。

  公开号：

  US07371755B1
• 作为产物：
  描述：

  3-羟甲基-5-甲基异恶唑 在 氢氧化钾 、 正丁基锂 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 48.25h， 生成 5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-(hydroxymethyl)isoxazole
  参考文献：
  名称：

  A model for compounds active against human rhinovirus-14 based on x-ray crystallography data

  摘要：

  A number of (oxazolinylphenyl)isoxazoles have been synthesized and tested against human rhinovirus-14 (HRV-14). Several of the more active compounds have been examined by X-ray crystallography and their orientation in the compound binding site on the capsid protein of HRV-14 has been determined. Based on the minimum inhibitory concentration against HRV-14 and the X-ray conformation of the compounds, a model has been developed which distinguishes between the space-filling properties of the active and inactive compounds in this series. The model was generated by overlaying composite structures and comparing the van der Waals generated volume maps. The results of this study indicate that inactive compounds display areas of excessive bulk particularly around the phenyl ring, while the active compounds occupy space below the pore area of the compound binding site.

  DOI：

  10.1021/jm00167a006

文献信息

• Haloalkoxy phenyl 4,5 dihydro oxazoles
  申请人：Sterling Drug Inc.

  公开号：US04939267A1

  公开（公告）日：1990-07-03

  Compounds of the formulas: ##STR1## wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed.

  上述公式中，化合物的公式为：##STR1## 其中Het是噁唑或噁嗪基团；X为O，S或SO，n为3至9的整数，Y为脂肪桥；各种R基团表示氢或如本文所述的各种取代基，对于抗病毒剂特别是针对小肠病毒具有用处。公式I化合物的N-(氯烷基)酰胺中间体也具有抗病毒活性。还公开了范围外的相关化合物。
• N-haloalkyl-4-(isoxazol-5-yl)alkoxy benzamides
  申请人：Sterling Drug, Inc.

  公开号：US05002960A1

  公开（公告）日：1991-03-26

  Compounds of the formulas: ##STR1## wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed. Also disclosed are novel intermediates, N-halo-alkyl-4-(isoxazol-5-yl)alkoxybenzamides, also useful as antiviral agents.

  分子式为##STR1##的化合物，在其中Het是噁唑或噁唑烷基；X是O，S或SO，n是从3到9的整数，Y是脂肪桥；各种R基代表氢或如下所述的各种取代基，对于抗病毒剂，特别是对于小肠病毒具有用处。Formula I化合物的N-(氯代烷基)酰胺中间体也是作为抗病毒剂活性的。还披露了范围外的相关化合物。还披露了新的中间体，N-卤代烷基-4-(异噁唑-5-基)烷氧基苯甲酰胺，也可作为抗病毒剂使用。
• Di-heterocyclic compounds and their use as antiviral agents
  申请人：Sterling Drug Inc.

  公开号：US04843087A1

  公开（公告）日：1989-06-27

  Compounds of the formulas: ##STR1## wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed.

  公式为：##STR1## 其中Het为噁唑或噁唑烷基团；X为O，S或SO，n为3到9的整数，Y为脂肪桥；各种R基代表氢或如此处所述的各种取代基，可用作抗病毒剂，特别是对抗小肠病毒。公式I化合物的N-(氯烷基)酰胺中间体也是抗病毒剂。还揭示了范围外的相关化合物。
• Isoxazole and furan derivatives, their preparation and use as antiviral agents
  申请人：STERLING WINTHROP INC.

  公开号：EP0207454A2

  公开（公告）日：1987-01-07

  Compounds of the formula are wherein: R is hydrogen or alkyl of 1 to 3 carbon atoms optionally substituted by hydroxy, lower-alkoxy, lower-alkoxyalkoxy, lower-acyloxy, halo or N=Z', wherein N=Z' is amino, lower- slkanoylamino, lower-alkylamino, di-lower-alkylamino, 1-pyrrolidyl, 1-piperidiny) or 4-morpholinyl; X is 0 or CH2; Y is an alkylene bridge of 3-9 carbon atoms, optionally interrupted by an olefinic linkage; Z is N or R5C, where R5 is hydrogen or lower-alkanoyl, with the proviso that when Z is N, R is other than hydrogen; m is 0 or 1; R, and R2 are each halogen, methyl, nitro, lower- alkoxycarbonyl or trifluoromethyl; and R3 and R4 are each hydrogen or lower-alkyl of 1-3 carbon atoms; and pharmaceutically acceptable acid-addition salts thereof, as well as methods for preparation and use thereof. The compound exhibit valuable antiviral properties.

  式中的化合物 其中 R 是氢或任选被羟基、低级烷氧基、低级烷氧基烷氧基、低级乙氧基、卤素或 N=Z' 取代的 1 至 3 个碳原子的烷基，其中 N=Z' 是氨基、低级烷酰氨基、低级烷基氨基、二低级烷基氨基、1-吡咯烷基、1-哌啶基或 4-吗啉基； X 是 0 或 CH2； Y 是 3-9 个碳原子的亚烷基桥，可选择被烯烃链节打断； Z 是 N 或 R5C，其中 R5 是氢或低级烷酰基，但当 Z 是 N 时，R 不是氢； m 为 0 或 1； R 和 R2 分别是卤素、甲基、硝基、低级烷氧羰基或三氟甲基；以及 R3 和 R4 分别是氢或 1-3 个碳原子的低级烷基；以及 其药学上可接受的酸加成盐及其制备和使用方法。这些化合物具有宝贵的抗病毒特性。
• ANTIVIRAL AGENTS
  申请人：BIOTA SCIENTIFIC MANAGEMENT PTY. LTD.

  公开号：EP1214317A1

  公开（公告）日：2002-06-19